Dr Maja Petkovic commented “The first FDA approved treatments were CAR-T cells directed against the B cell protein CD19. This ...
WuXi Biologics, a global CRDMO, has launched TrueSite TI, a targeted integration (TI)-based CHO cell line platform.
The reference-quality genome assembly of an experimentally relevant human cell line, retinal pigment epithelial line RPE-1, is completed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback